First Time Loading...

Fusion Antibodies PLC
LSE:FAB

Watchlist Manager
Fusion Antibodies PLC Logo
Fusion Antibodies PLC
LSE:FAB
Watchlist
Price: 3.35 GBX
Updated: Jun 13, 2024
Have any thoughts about
Fusion Antibodies PLC?
Write Note

ROE
Return on Equity

-140.9%
Current
-65%
Average
-3.5%
Industry

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
-140.9%
=
Net Income
-2.8m
/
Equity
1.3m

ROE Across Competitors

Country UK
Market Cap 3.2m GBP
ROE
-141%
Country US
Market Cap 219.8B USD
ROE
13%
Country US
Market Cap 196B USD
ROE
16%
Country US
Market Cap 39.6B USD
ROE
22%
Country CH
Market Cap 34.8B CHF
ROE
7%
Country US
Market Cap 38.8B USD
ROE
21%
Country KR
Market Cap 52.8T KRW
ROE
9%
Country US
Market Cap 31.2B USD
ROE
-849%
Country IE
Market Cap 26.4B USD
ROE
8%
Country US
Market Cap 24.7B USD
ROE
21%
Country CN
Market Cap 133.3B CNY
ROE
18%

Profitability Report

View the profitability report to see the full profitability analysis for Fusion Antibodies PLC.

See Also

Discover More
What is Return on Equity?

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
-140.9%
=
Net Income
-2.8m
/
Equity
1.3m
What is the ROE of Fusion Antibodies PLC?

Based on Fusion Antibodies PLC's most recent financial statements, the company has ROE of -140.9%.